Silence Therapeutics plc Share Price
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 16/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 12.46 USD | -4.59% |
|
-8.98% | +104.93% |
| Market Cap | 56Cr 75Cr 65Cr 61Cr 104.41Cr 7.2TCr 105.19Cr 733.29Cr 282.12Cr 3.65TCr 281.8Cr 275.55Cr 12TCr | P/E 2026 * |
-23.4x | P/E 2027 * | -18.8x |
|---|---|---|---|---|---|
| Enterprise Value | 42Cr 57Cr 49Cr 47Cr 79Cr 5.47TCr 80Cr 557.86Cr 214.62Cr 2.78TCr 214.38Cr 209.63Cr 8.85TCr | EV / Sales 2026 * |
1,313x | EV / Sales 2027 * | 509x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SLN | Delayed | |
CBOE
| SLN | Real-time | |
|
Tradegate
| XRP2 | Real-time | |
|
Deutsche Boerse AG
| XRP2 | Delayed | |
|
Börse Stuttgart
| XRP2 | Delayed | |
|
Boerse Muenchen
| XRP2 | Real-time |
Last Transcript: Silence Therapeutics plc
| 1 day | -4.59% | ||
| 1 week | -8.98% | ||
| Current month | -7.91% | ||
| 1 month | -9.18% | ||
| 3 months | +78.00% | ||
| 6 months | +80.58% | ||
| Current year | +104.93% |
| 1 week | 12.1 |  | 13.81 |
| 1 month | 12.1 | | 15.28 |
| Current year | 4.19 | | 17.58 |
| 1 year | 4.19 | | 17.58 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/07/26 | Sell | 8,65,112 | 0.6105% | |||
| 02/01/26 | Free | Chief Financial Officer | 3,75,000 | 0.2646% | ||
| 02/01/26 | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.59% | -8.98% | +163.42% | +25.23% | 75Cr | |
| +0.56% | -3.38% | -1.83% | +8.00% | 4.58TCr | |
| -0.12% | -1.19% | +343.42% | +545.03% | 4.39TCr | |
| +1.51% | +4.04% | +45.01% | +27.38% | 4.44TCr | |
| -2.07% | -1.42% | +4.28% | +72.97% | 3.94TCr | |
| -0.73% | -3.06% | +9.63% | +38.92% | 3.13TCr | |
| -9.49% | -11.23% | - | - | 1.57TCr | |
| +4.21% | +5.01% | +24.99% | +121.62% | 1.73TCr | |
| +1.83% | +3.20% | +16.49% | +32.73% | 1.47TCr | |
| -0.08% | -2.81% | +79.24% | +31.27% | 1.3TCr | |
| Average | -0.90% | -1.98% | +76.07% | +100.35% | 2.66TCr | |
| Weighted average by Cap. | -0.27% | -1.25% | +76.99% | +130.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.17Cr 6L 42.5L 16.35L 2.11Cr 16.33L 15.97L 6.74Cr | 8L 10.12L 9L 8L 14.09L 9.71Cr 14.19L 98.93L 38.06L 4.92Cr 38.02L 37.18L 16Cr |
| Net income | -4.21Cr -5.68Cr -4.92Cr -4.65Cr -7.91Cr -545.06Cr -7.97Cr -56Cr -21Cr -276.38Cr -21Cr -21Cr -881.41Cr | -7.1Cr -9.58Cr -8.29Cr -7.84Cr -13Cr -918.59Cr -13Cr -94Cr -36Cr -465.77Cr -36Cr -35Cr -1.49TCr |
| Net Debt | -13Cr -18Cr -16Cr -15Cr -25Cr -1.72TCr -25Cr -175.43Cr -67Cr -872.98Cr -67Cr -66Cr -2.78TCr | -17Cr -23Cr -20Cr -19Cr -33Cr -2.25TCr -33Cr -229.41Cr -88Cr -1.14TCr -88Cr -86Cr -3.64TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | $12.46 | -4.59% | 13,83,436 |
| 14/26/14 | $13.06 | +0.31% | 10,95,255 |
| 11/26/11 | $13.02 | -2.18% | 6,85,914 |
| 10/26/10 | $13.31 | -1.77% | 6,82,632 |
| 09/26/09 | $13.55 | -1.02% | 6,45,880 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Select your edition
All financial news and data tailored to specific country editions
